Literature DB >> 15689617

cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues.

Ming-Chang Chiang1, Yi-Chao Lee, Chuen-Lin Huang, Yijuang Chern.   

Abstract

Huntington's disease is a neurodegenerative disease resulting from a CAG (glutamine) trinucleotide expansion in exon 1 of the Huntingtin (Htt) gene. The role of the striatum-enriched A2A adenosine receptor (A2A-R) in Huntington's disease has attracted much attention lately. In the present study, we found that expression of mutant Htt with expanded poly(Q) significantly reduced the transcript levels of the endogenous A2A-R in PC12 cells and primary striatal neurons. Cotransfection of various promoter constructs of the A2A-R gene and an expression construct of poly(Q)-expanded Htt revealed that the Htt mutant suppressed the core promoter activity of the A2A-R gene. Stimulation of the A2A-R using CGS21680, forskolin, and a constitutively active cAMP-response element-binding protein (CREB) mutant elevated the reduced promoter activity of the A2A-R gene by mutant Htt. Moreover, the effect of CGS was blocked by an A2A-R-selective antagonist (CSC), two inhibitors of protein kinase A, and two dominant negative mutants of (CREB). The protein kinase A/CREB pathway therefore is involved in regulating A2A-R promoter activity. Consistently, an atypical CRE site (TCCAGG) is located in the core promoter region of the A2A-R gene. Electrophoretic gel mobility shift assay and mutational inactivation further demonstrated the functional binding of CREB to the core promoter region and showed that expression of poly(Q)-expanded Htt abolished the binding of CREB to this site. Stimulation of the A2A-R restored the reduced CREB binding caused by the mutant and concurrently reduced mutant Htt aggregation. Collectively, the poly(Q)-expanded mutant Htt suppressed expression of the A2A-R by inhibiting its core promoter at least partially by preventing CREB binding.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15689617     DOI: 10.1074/jbc.M413279200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

2.  Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling.

Authors:  Bogachan Sahin; Stacey Galdi; Joseph Hendrick; Robert W Greene; Gretchen L Snyder; James A Bibb
Journal:  Brain Res       Date:  2006-12-06       Impact factor: 3.252

Review 3.  Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Miklós Palkovits; Alexander O Tarakanov; Francisco Ciruela; Luigi F Agnati
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

4.  Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R.

Authors:  Eugen Kloster; Carsten Saft; Denis A Akkad; Jörg T Epplen; Larissa Arning
Journal:  J Mol Med (Berl)       Date:  2014-02       Impact factor: 4.599

5.  Early Downregulation of p75NTR by Genetic and Pharmacological Approaches Delays the Onset of Motor Deficits and Striatal Dysfunction in Huntington's Disease Mice.

Authors:  Nuria Suelves; Andrés Miguez; Saray López-Benito; Gerardo García-Díaz Barriga; Albert Giralt; Elena Alvarez-Periel; Juan Carlos Arévalo; Jordi Alberch; Silvia Ginés; Verónica Brito
Journal:  Mol Neurobiol       Date:  2018-05-27       Impact factor: 5.590

Review 6.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

7.  Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease.

Authors:  Jiun-Tsai Lin; Wei-Cheng Chang; Hui-Mei Chen; Hsing-Lin Lai; Chih-Yeh Chen; Mi-Hua Tao; Yijuang Chern
Journal:  Mol Cell Biol       Date:  2012-12-28       Impact factor: 4.272

8.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

Review 9.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

10.  Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.

Authors:  Xavier Guitart; Jordi Bonaventura; William Rea; Marco Orrú; Lucrezia Cellai; Ilaria Dettori; Felicita Pedata; Marc Brugarolas; Antonio Cortés; Vicent Casadó; Ching-Pang Chang; Manikandan Narayanan; Yijuang Chern; Sergi Ferré
Journal:  Neurobiol Dis       Date:  2016-08-24       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.